Company Profile

Bioscience Development Inc
Profile last edited on: 1/14/19      CAGE: 42UP1      UEI: TRCELQ72NMC3

Business Identifier: Therapies based on interplay between microbes and human immune system.
Year Founded
2000
First Award
2000
Latest Award
2020
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1467 3rd Avenue Suite 1R
New York, NY 10028
   (212) 452-1731
   schultzer@umdnj.edu
   N/A
Location: Single
Congr. District: 12
County: New York

Public Profile

Bioscience Development Inc's PI, Steven E Schutzer, is currently a professor of Medicine in the allergy, immunology, and rheumatology department of Rutgers University's New Jersey Medical School. Schutzer's research focuses on the relation between the body's immune system and microbes, including potential applications for treating Lyme Disease and Multiple Sclerosis (MS). Particular areas of research interest are Lyme and Tick diseases, neuroimmunology, and immunology.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2020 2 NIH $3,286,455
Project Title: Development of Molecular Diagnostic Test for Early Onset of Lyme Disease
2015 1 NIH $299,998
Project Title: Development of Diagnostic Test for Early Multiple Sclerosis
2006 2 NIH $988,500
Project Title: Detection of Virulent Burkholderia mallei
2005 2 NIH $896,880
Project Title: Assay To Detect Acute Active Lyme Disease
2003 1 NIH $158,940
Project Title: Assay to detect early neurologic Lyme disease

Key People / Management

  Barbara A Body

  Steven E Schutzer -- Principal

Company News

There are no news available.